Business
Eledon Pharmaceuticals Announces Upcoming Presentations on AT-1501 at the Virtual 2021 American Transplant Congress
IRVINE, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on
About this update from Eledon Pharmaceuticals, Inc.
[{"type":"text","content":"IRVINE, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), announced upcoming presentations covering AT-1501, its lead product candidate, at the American Transplant Congress (ATC), which is being held virtually from June 4-9, 2021. Accepted oral presentations include Phase 1 data on the safety, tolerability and pharmacokinetics of AT -1501, and pre-clinical data showing the effectiveness of AT-1501 in preventing islet allograft rejection in nonhuman primate models. In addition, two posters will report on pre-clinical pharmacokinetics, toxicity, and characterization of AT-1501 binding and Fc effector function. The abstracts and additional information can be found on the ATC website at https://atcmeeting.org. ORAL PRESENTATIONS Title: A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-1501 Date and Time: Monday, June 7, 6:00 PM – 6:05 PM ESTPresenter: Steven Perrin, Ph.D., Eledon PharmaceuticalsSession Title: Kidney ImmunosuppressionAbstract: 273 Title: AT-1501, a Novel and Clinically Applicable CD40L Specific Monoclonal Antibody, Promotes Islet Allograft Survival in Nonhuman Primates Date and Time: Tuesday, June 8, 6:05 PM – 6:10 PM ESTPresenter: Norma Sue Kenyon, Ph.D., Professor of Surgery, Microbiology & Immunology and Biomedical Engineering, University of Miami, Miami, FLSession Title: Xenotransplantation and Preclinical StudiesAbstract: 343 POSTER PRESENTATIONS Title: Pharmacokinetic and Toxicity Studies of an Anti-CD40L Antibody, AT-1501 in Rhesus Macaques Presenter: Steve Perrin, Ph.D., Eledon PharmaceuticalsSession Title: Acute RejectionAbstract: 506 Title: The Development and Characterization of AT-1501, an Anti-CD40L Antibody Lacking Fc Effector Function Presenter: Steven Perrin, Ph.D., Eledon PharmaceuticalsSession Title: Antigen Presentation/Allorecognition/Dendritic CellAbstract: 512 About Eledon Pharmaceuticals and AT-1501 Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patien...